Skip to content
OpenCapital
Get started

Kiniksa Pharmaceuticals International, plc KNSA EBITDA margin

EBITDA margin at other companies

Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
46.6%+37.6pp
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
-681.6%+642pp
BridgeBio Pharma logo
BridgeBio PharmaBBIO
-89.6%-40.8pp
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-32%-10.7pp
LQD
Liquidia CorporationLQDA
-152.5%-66.9pp
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
51.2%+0.9pp

Other financials

Income statement

See full
Revenue$214.3M+55.5%
Gross profit$193.5M+61.3%
Operating income$29.3M+121%
Net income$22.6M+165%
EPS (diluted)$0.27+145%

Balance sheet

See full
Cash & equivalents$190.0M+20.9%
Total debt$9.0M-9.0%
Total equity$605.7M+32.4%
Total assets$825.3M+37.7%

Cash flow

See full
Operating cash flow$50.2M+125%
CapEx$161.0K+62.6%
Free cash flow$50.0M+125%

Valuation

See full
Market cap$4.58B+128%

Profitability

See full
Gross margin89.3%+3.5pp
Operating margin12.4%+10.2pp
Net margin9.7%+7.6pp
FCF margin21.8%+12.2pp

Returns & leverage

See full
Return on equity13.7%+11.3pp
Debt / equity0×0.0×
Current ratio3.8×+0.1×

Where this comes from

Calculated from Kiniksa Pharmaceuticals International, plc’s reported figures.

ebitda/total revenue=12.6%

Based on trailing twelve months.

The official record: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kiniksa Pharmaceuticals International, plc's ebitda margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kiniksa Pharmaceuticals International, plc's EBITDA margin?
Kiniksa Pharmaceuticals International, plc (KNSA) reported EBITDA margin of 12.6% in Q1 2026.
How has Kiniksa Pharmaceuticals International, plc's EBITDA margin changed year-over-year?
Kiniksa Pharmaceuticals International, plc's EBITDA margin increased by 525.6% year-over-year, from -3% to 12.6%.
What is the long-term trend for Kiniksa Pharmaceuticals International, plc's EBITDA margin?
Over 4 years (2021 to 2025), Kiniksa Pharmaceuticals International, plc's EBITDA margin has grown at a -58.7% compound annual growth rate (CAGR), from -400.3% to 11.6%.
What does EBITDA margin mean?
EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.